Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Lachlan Clive Campbell has worked on the following 43 EPO patent applications which have been published in the last five years:

EP11743481

2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF

IPC classification:
A61K 31/381, A61P 31/12, C07D 409/04, C07D 409/14, C07D 413/04, C07D 413/14, C07D 417/14, C07D 487/04, C07D 498/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11741554

BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS

IPC classification:
A61K 31/404, A61K 31/4184, C07D 215/36, C07D 235/18, C07D 263/57, C07D 401/04, C07D 401/12, C07D 403/04, C07D 405/04, C07D 413/12, C07D 471/04, C07D 513/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
The patent has been granted
EP11773361

VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS

IPC classification:
A61K 31/355, A61K 31/403, A61K 45/06, A61P 31/22
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12704135

NOVEL HETEROCYCLIC DERIVATIVES

IPC classification:
A61K 31/519, A61P 35/00, C07D 487/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
PATENT GRANTED
EP12719083

GLYCOSIDE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF DIABETES

IPC classification:
A61K 31/70, A61P 3/10, C07D 405/10
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP12748260

NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

IPC classification:
A61K 31/4245, A61P 3/00, A61P 25/28, C07D 271/06, C07D 413/10, C07D 413/12
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12770249

BENZOTHIAZOLONE COMPOUND

IPC classification:
A61K 31/428, A61P 21/00, C07D 277/68
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP12791856

NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

IPC classification:
A61K 31/5375, A61P 25/00, C07D 265/30, C07D 413/04, C07D 413/12, C07D 413/14, C07D 417/12, C07D 471/04, C07D 487/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12798854

NOVEL PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

IPC classification:
C07D 473/16, C07D 519/00
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12805774

NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

IPC classification:
A61K 31/4245, A61P 25/28, C07D 413/04, C07D 413/14
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
PATENT GRANTED
EP11711322

COMPOSITION COMPRISING THE AMYLOID BETA 1-6 PEPTIDE COUPLED TO A VIRUS-LIKE PARTICLE AND AN ADJUVANT

IPC classification:
A61K 39/00, A61K 47/48, A61P 25/28
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13741412

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

IPC classification:
A61K 31/4355, A61K 31/436, A61K 31/4365, A61K 31/437, A61K 31/4375, A61K 31/519, A61P 25/02, A61P 25/04, A61P 35/00, C07D 211/60, C07D 211/66, C07D 471/04, C07D 491/048, C07D 491/056, C07D 495/04
Applicant:
Novartis AG
Agent:
Philippe Becker, Cabinet Becker & Associés
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13741446

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

IPC classification:
A61K 31/496, A61K 31/4985, A61K 31/551, A61P 25/02, A61P 25/04, A61P 35/00, C07D 241/04, C07D 243/08, C07D 403/04, C07D 413/04, C07D 413/06, C07D 487/04
Applicant:
Novartis AG
Agent:
Philippe Becker, Cabinet Becker & Associés
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12772462

2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS

IPC classification:
A61K 31/5355, A61K 45/06, A61P 3/04, A61P 3/10, A61P 9/12, A61P 25/28, C07D 413/14
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13721227

TETRAHYDROPYRAN DGAT1 INHIBITORS

IPC classification:
A61K 31/422, A61K 31/4245, A61P 3/00, A61P 3/04, A61P 3/10, A61P 31/22, C07D 413/12
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13727385

CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS

IPC classification:
A61K 31/422, A61K 31/4245, A61P 3/00, A61P 3/04, A61P 3/10, C07D 413/12, C07D 417/12
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
PATENT GRANTED
EP13812075

SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST

IPC classification:
A61K 31/428, A61P 21/00, C07D 277/68
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13792084

INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF

IPC classification:
A61K 31/403, A61P 31/06, C07D 209/42
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12708688

CRYSTALLINE OXAZINE DERIVATIVE AND ITS USE AS BACE INHIBITOR

IPC classification:
A61K 31/5377, A61K 45/06, A61P 25/00, C07D 413/12
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13826612

PYRIMIDO [4,5-B]QUINOLINE-4,5 (3H,10H)-DIONES AS NONSENSE MUTATION SUPPRESSORS

IPC classification:
A61K 31/513, A61P 7/00, A61P 21/00, A61P 35/00, A61P 43/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14164980

Gamma secretase inhibitors for treating respiratory diseases

IPC classification:
A61K 31/00, A61K 31/145, A61K 31/381, A61K 31/4164, A61K 31/4245, A61K 31/55, A61P 11/00, A61P 11/06
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP14701273

MEGLUMINE SALT FORMS OF 2-((1 R,4R)-4-(4-(5-(BENZOXAZOL-2-YLAMINO)PYRIDIN-2-YL)PHENYL)CYCLOHEXYL) ACETIC ACID AND THEIR USE AS DGAT1 INHIBITORS

IPC classification:
A61K 31/4439, A61P 3/04, A61P 3/10, C07D 413/12
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14704959

THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS

IPC classification:
A61K 31/433, A61K 31/454, A61K 31/496, A61P 21/00, C07D 417/10, C07D 417/12, C07D 417/14, C07D 487/04, C07D 487/10
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14708700

FORMULATION COMPRISING BENZOTHIAZOLONE COMPOUND

IPC classification:
A61K 9/20, A61K 9/48, A61K 31/428
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP15182564

ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS

IPC classification:
A61K 31/44, A61K 31/443, A61K 31/4436, A61K 31/4439, A61P 9/12, C07D 213/30, C07D 213/57, C07D 213/61, C07D 401/04, C07D 405/04, C07D 409/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12700390

NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS

IPC classification:
A61K 31/5377, A61P 25/00, C07D 413/14, C07D 471/04, C07D 487/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14823688

HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE

IPC classification:
A61K 31/4375, A61K 31/472, A61K 31/522, A61P 25/02, C07D 217/26
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP15197854

2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS

IPC classification:
A61K 31/5355, A61P 3/04, A61P 3/10, A61P 9/12, A61P 25/28, C07D 413/14
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
PATENT GRANTED
EP12700194

BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS

IPC classification:
A61K 31/497, A61K 31/5375, A61K 31/5377, A61K 31/553, A61P 1/18
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14750931

1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS

IPC classification:
A61K 31/501, A61P 21/00, C07D 401/04, C07D 401/14, C07D 405/14, C07D 413/14, C07D 487/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11715244

FUROPYRIDINE COMPOUNDS AND USES THEREOF

IPC classification:
A61K 31/4355, A61K 31/541, A61P 31/14, A61P 35/00, C07D 491/048, C07D 491/147
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
No opposition filed within time limit
EP14806081

RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS

IPC classification:
A61K 31/4353, A61K 31/437, A61K 31/4375, A61K 31/501, A61K 31/506, A61K 31/5377, A61K 31/5383, A61P 35/00, C07D 471/04, C07D 498/04, C07D 519/00
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP12705457

COMBINATIONS OF THERAPEUTIC AGENTS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

IPC classification:
A61K 31/436, A61K 31/4745, A61K 31/496, A61K 31/52, A61K 31/5377, A61K 45/06, A61P 25/00
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12700232

OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS

IPC classification:
A61K 31/437, A61K 31/444, A61K 31/497, A61K 31/5377, A61P 25/00, C07D 413/12, C07D 471/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15727117

COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS

IPC classification:
A61K 31/352, A61K 31/415, A61K 31/4245, A61K 31/44, A61K 31/506, A61P 19/02, C07D 491/18, C07D 493/08
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15774680

CARBOXAMIDE DERIVATIVES

IPC classification:
A61K 31/4192, A61P 9/12, A61P 19/02, A61P 19/04, A61P 19/08, C07D 403/12, C07D 487/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15725195

CARBOXAMIDE DERIVATIVES

IPC classification:
A61K 31/4155, A61K 31/422, A61P 9/12, A61P 11/00, A61P 19/02, A61P 19/08, C07D 413/12, C07D 413/14
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15731119

PYRIDOPYRIMIDINEDIONE DERIVATIVES

IPC classification:
A61K 31/38, A61K 31/505, C07D 471/04, C07D 495/14
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15731121

NAPHTHYRIDINEDIONE DERIVATIVES

IPC classification:
A61K 31/44, C07D 471/04, C07D 471/14, C07D 495/14
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15731120

PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES

IPC classification:
A61K 31/519, C07D 471/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature